West and AbbVie Finalize Deal for SmartDose 3.5mL On‑Body Delivery System Rights

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in injectable drug delivery solutions, has signed a definitive agreement to sell the manufacturing and supply rights — including associated facilities — for its SmartDose® 3.5mL On‑Body Delivery System to AbbVie (NYSE: ABBV) for $112.5 million, subject to working capital and other customary adjustments. The transaction is expected to close in mid‑2026, pending fulfillment of closing conditions. West will continue the commercial supply of the SmartDose 3.5mL system and execute existing project commitments before closing, which may include milestone‑based payments. The SmartDose 3.5mL product is anticipated to represent approximately 4% of West’s fiscal 2025 revenues. Eric M. Green, West’s President and CEO, emphasized that West pioneered the on‑body delivery technology and that transitioning this product to AbbVie supports its strategic portfolio focus and ongoing pipeline development. West will retain rights to other SmartDose versions, including the SmartDose® 10mL system for larger volume drug delivery. #PharmaDeal #SmartDose #WestPharma #AbbVie #SlimScan #GrowthStocks #CANSLIM